Oncolytic Viruses

Introduction to Oncolytic Virotherapy.- Methods for Modification of Therapeutic Viruses.- Tumor Targeting of Oncolytic Adenoviruses using Bispecific Adapter Proteins.- Development of Entry-targeted Oncolytic Measles Viruses.- Insert Stability and In Vivo Testing of MicroRNA-Detargeted Oncolytic Picornaviruses.- Ex vivo Virotherapy with Myxoma Virus to Treat Cancer.- Immunomodulation in Oncolytic Measles Virotherapy.- A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death.- Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.- Analysis of Immunological Treatment Effects of Virotherapy in Tumor Tissue.- Immunohistochemistry for Tumor-infiltrating Immune Cells after Oncolytic Virotherapy.- Detection of Tumor Antigen-specific T-cell Responses after Oncolytic Vaccination.- Evaluation of Oncolytic Virus Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models.- Delivery of Oncolytic Reovirus by Cell Carriers.- In Vivo Bioimaging for Monitoring Intratumoral Virus Activity.- Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 virus: Using a Bladder Tumour Precision-cut Slice Model System to Assess Viral Efficacy.- Use of Liquid Patient Ascites Fluids as a Pre-clinical Model for Oncolytic Virus Activity.- Generating Primary Models of Human Cancer to Aid in the Development of Clinically-relevant Oncolytic Viruses.- Considerations for Clinical Translation of MG1 Maraba Virus.- Fluorescence in Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-treated Human Brain Tumors.- Mathematical Modeling of Oncolytic Virotherapy.